Pharma News

“Today is a historic day, an inflection point in the journey of "Atmanirbharta" in the pharma & medical devices sector. We need to transform Indian Pharma & MedTech sectors from a cost-based to a value-based & innovation-based industry.” This was stated by Dr.

Biosergen AB (Biosergen) and Alkem Laboratories Ltd. (Alkem) are pleased to announce the signing of a co-development and license agreement for BSG005, an innovative polyene macrolide, through phase II and phase III trials for sale in the Indian market. 

Antibiotic resistant bacteria are a threat to human lives, and yet the development of new drugs to treat bacterial infections is slow. A group of proven drugs used in cancer treatment for decades could possibly be the solution. A new class of antibiotics is now being developed by researchers at Linköping University in Sweden.

Ceftazidime in combination with avibactam is a last-line antibiotic, to be used as a targeted therapy for certain carbapenem-resistant Gram-negative infections and not to be used as an empirical therapy. But the antibiotic recently lost its exclusivity and became a generic drug in India. And scientists from ICMR are foreseeing certain potential adverse implications of introducing generic versions of ceftazidime/avibactam into the Indian market.

A research team led by scientists from City University of Hong Kong (CityU) has achieved a significant breakthrough by inventing a new class of near-infrared-activated photo-oxidants that can effectively kill cancer cells without requiring oxygen. The photo-oxidants induce a unique form of cancer cell death that can overcome cancer cell resistance. The findings offer a new strategy, called ‘photo-oxidation therapy’, and provide a promising direction for the development of anti-cancer drugs.

Max Planck Scientists from Dortmund show how the signaling molecules BMP and FGF act as antagonists during embryonic development and thus guide cell differentiation

A research team at the University of Basel and the SIB Swiss Institute of Bioinformatics uncovered a treasure trove of uncharacterized proteins. Embracing the recent deep learning revolution, they discovered hundreds of new protein families and even a novel predicted protein fold.

Adults with atopic dermatitis (AD) have a 34 percent increased risk of developing new-onset inflammatory bowel disease (IBD) compared with individuals who do not have the skin condition, and children have a 44 percent increased risk, according to a new study from the Perelman School of Medicine at the University of Pennsylvania. Additionally, as the severity of AD increased, the risk of developing IBD rose.

GSK plc announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anaemia. Ojjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor.